Blueprint
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
For the month of September 2016
 
Commission File Number:  001-11960
 
AstraZeneca PLC
 
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
 United Kingdom
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X            Form 40-F  __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):            
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes  __                 No X
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):   82-_____________
 
 
 
28 September 2016 07:00
 
 
CHANGE TO ASTRAZENECA BOARD OF DIRECTORS
 
AstraZeneca today announced that Dr Cornelia (Cori) Bargmann, a Non-Executive Director, will step down from the Board of AstraZeneca PLC and as a member of the Company's Science Committee with effect from 1 October 2016. Dr Bargmann recently accepted a new position as President of Chan Zuckerberg Science, part of the Chan Zuckerberg Initiative.
 
Leif Johansson, AstraZeneca Chairman, said: "We congratulate Cori on her new appointment and thank her for her contribution to AstraZeneca in the last 18 months. We are sorry to see her leave the AstraZeneca Board but fully understand her decision to step down to focus on her new assignment."
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
 
CONTACTS
 
Media Enquiries
 
 
 
Neil Burrows
 
UK/Global
+44 203 749 5637
Vanessa Rhodes
 
UK/Global
+44 203 749 5736
Karen Birmingham
 
UK/Global
+44 203 749 5634
Rob Skelding
 
UK/Global
+44 203 749 5821
Jacob Lund
 
Sweden
+46 8 553 260 20
Michele Meixell
 
US
+1 302 885 2677
Investor Relations
 
 
 
UK
 
 
 
Thomas Kudsk Larsen
 
 
+44 203 749 5712
Craig Marks
 
Finance, Fixed Income, M&A
+44 7881 615 764
Nick Stone
 
Respiratory & Autoimmunity
+44 203 749 5716
Henry Wheeler
 
Oncology
+44 203 749 5797
Christer Gruvris
 
Infection & Neuroscience
+44 203 749 5711
US
 
 
 
Lindsey Trickett
 
Cardiovascular & Metabolic Diseases
+1 240 543 7970
Mitchell Chan
 
Oncology
+1 240 477 3771
Toll-free
 
+1 866 381 7277
 
Adrian Kemp
Company Secretary
AstraZeneca PLC
 
 
-ENDS-
 
SIGNATURES
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
AstraZeneca PLC
 
 
 
Date: 28 September 2016
 
By:  /s/ Adrian Kemp
Name: Adrian Kemp
Title: Company Secretary